Oxford, UK. Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, today announced that its CEO, Dr. Richard Pither is to present at BioTrinity on Wednesday, May 13th 2015 at Novotel London West from 13:40 in Room D4/D5 Lalande/Talbot, Second Floor. Details can be found at http://biotrinity.com/company-showcase-4/
Dr. Pither will provide an update on the substantial progress made by Cytox in recent months in developing a genetic blood-based biomarker test for Alzheimer’s disease risk. This work is being carried out in partnership with Dr. Zsuzsanna Nagy (University of Birmingham) and Professor John Hardy (UCL) and is being supported by the recent funding awarded by Innovate UK.
The update will include a review of the science underpinning the development, an overview of the clinical plans and an update on recent fund-raising activities.